BackRoyalty Pharma plc Overview

Royalty Pharma plc Intangible Assets

Latest intangible assets for RPRX: $17B.

Get informed when a big investor buys or sells

+ Follow
Intangible Assets
$16.54B

Peer average

Loading

Royalty Pharma plc Intangible Assets History

Loading

Royalty Pharma plc vs. peers: Intangible Assets Comparison

Loading

Royalty Pharma plc Intangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Royalty Pharma plc (RPRX) FAQ

As of the most recent data (March 2026), RPRX shows a intangible assets of $17B. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RPRX's intangible assets is now $17B (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Royalty Pharma plc is outperforming or lagging.

Tracking RPRX's intangible assets over time shows whether Royalty Pharma plc is scaling, shrinking, or reshaping that part of the business. The current reading is $17B In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this intangible assets page, Stockcircle has Royalty Pharma plc's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect intangible assets (currently $17B) with ownership activity and broader fundamentals.

Royalty Pharma plc's intangible assets is $17B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.